{"id":46415,"date":"2022-07-21T07:01:39","date_gmt":"2022-07-21T05:01:39","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/second-innate-pharma-nk-cell-engager-selected-by-sanofi-as-drug-candidate-for-development\/"},"modified":"2022-07-21T07:01:39","modified_gmt":"2022-07-21T05:01:39","slug":"second-innate-pharma-nk-cell-engager-selected-by-sanofi-as-drug-candidate-for-development","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/second-innate-pharma-nk-cell-engager-selected-by-sanofi-as-drug-candidate-for-development\/","title":{"rendered":"Second Innate Pharma NK Cell Engager Selected by Sanofi as Drug Candidate for Development"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<b>IPH6401\/SAR\u2019514 is a BCMA-targeting NK cell engager using Sanofi\u2019s proprietary CROSSODILE<sup>\u00ae<\/sup> multi-functional platform. It was developed jointly and benefits from the dual NK targeting of Innate\u2019s ANKET<sup>TM<\/sup> proprietary platform<\/b>\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Selection of IPH6401\/SAR\u2019514 triggers a \u20ac3M milestone payment to Innate<\/b>\n<\/li>\n<\/ul>\n<p>MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News:\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220706005771\/en\/1245155\/4\/INNATEvertnoirDS.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220706005771\/en\/1245155\/21\/INNATEvertnoirDS.jpg\"><\/a><\/p>\n<p>\nInnate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201c<b>Innate<\/b>\u201d or the \u201c<b>Company<\/b>\u201d) today announced that Sanofi has made the decision to progress IPH6401\/SAR\u2019514 into investigational new drug (IND)-enabling studies, triggering a \u20ac3 million milestone payment.\n<\/p>\n<p>\nIPH6401\/SAR\u2019514 is a BCMA-targeting NK cell engager using Sanofi\u2019s proprietary CROSSODILE<sup>\u00ae<\/sup> multi-functional platform, which comprises the Cross-Over-Dual-Variable-Domain (CODV) format. It induces a dual targeting of the NK activating receptors, NKp46 and CD16, for an optimized NK cell activation, based on Innate\u2019s ANKET<sup>TM<\/sup> (Antibody-based NK cell Engager Therapeutics) proprietary platform. NK cell engagers are an alternative for cancer treatment aiming to offer an improved therapeutic window as compared to bispecific T lymphocyte-engaging formats.\n<\/p>\n<p>\nIPH6401\/SAR\u2019514 has shown anti-tumor activity and promising drug properties in pre-clinical models. Sanofi will be responsible for all future development, manufacturing and commercialization of IPH6401\/SAR\u2019514.\n<\/p>\n<p>\n\u201c<i>We are pleased that Sanofi has chosen to progress <\/i><i>IPH6401\/SAR\u2019514 into development, building on our strong partnership which brought<\/i><i> the first NKp46-based NK cell engager to the clinic last year<\/i>,\u201d said <b>Pr. Eric Vivier, DVM-PhD, Chief Scientific Officer at Innate Pharma<\/b>. \u201c<i>Innate\/Sanofi\u2019s collaboration integrating Sanofi&#8217;s multi-functional CODV format and the dual NK cell targeting based on Innate&#8217;s multifunctional ANKET platform<\/i><i> <\/i><i>is creating an entirely new class of molecules to induce synthetic immunity against cancer, which have been designed to belong to the next wave of impactful medicines in immunotherapy<\/i>.\u201d\n<\/p>\n<p>\nThis milestone is part of the <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.innate-pharma.com%2Fnode%2F2150&amp;esheet=52772896&amp;newsitemid=20220706005771&amp;lan=en-US&amp;anchor=previously+announced&amp;index=1&amp;md5=23c1803d451710f6c4a530f2ebbc03d1\" rel=\"nofollow noopener\" shape=\"rect\">previously announced<\/a> research collaboration with Sanofi, under which the companies collaborate on the generation and evaluation of up to two bispecific NK cell engagers, using the ANKET platform from Innate that simultaneously targets two NK activating receptors, NKp46 and CD16, to optimize NK cell activation and Sanofi\u2019s proprietary antibody format as well as anti-tumor target antibodies. In 2021, the companies announced plans to develop IPH6101\/SAR\u2019579, which is <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.innate-pharma.com%2Fmedia%2Fall-press-releases%2Ffirst-patient-dosed-iph6101%2Fsar443579-phase-1%2F2-clinical-trial-various-blood-cancers&amp;esheet=52772896&amp;newsitemid=20220706005771&amp;lan=en-US&amp;anchor=in+Phase+1%2F2&amp;index=2&amp;md5=e50a0b83cce8c55ecb3396296309320a\" rel=\"nofollow noopener\" shape=\"rect\">in Phase 1\/2<\/a> in relapsed or refractory acute myeloid leukemia (R\/R AML), B-cell acute lymphoblastic leukemia (B-ALL) and high risk-myelodysplastic syndrome (HR-MDS).\n<\/p>\n<div class=\"bwpagebreakafter\">\n<\/div>\n<p>\n<b>About the Innate-Sanofi agreement:<\/b>\n<\/p>\n<p>\nThe Company has a research collaboration and licensing agreement with Sanofi to apply Innate\u2019s proprietary platform to the development of innovative multi-specific antibody formats engaging NK cells through the activating receptors NKp46 and CD16 to kill tumor cells now called the ANKET platform.\n<\/p>\n<p>\nUnder the terms of the license agreement, Sanofi will be responsible for the development, manufacturing and commercialization of products resulting from the research collaboration. Innate Pharma will be eligible to up to \u20ac400m in development and commercial milestone payments as well as royalties on net sales.\n<\/p>\n<p>\n<b>About ANKET<sup>TM<\/sup>:<\/b>\n<\/p>\n<p>\nANKET<sup>TM<\/sup> (<b>A<\/b>ntibody-based <b>NK<\/b> cell <b>E<\/b>ngager <b>T<\/b>herapeutics) is Innate&#8217;s proprietary platform for developing next-generation, multi-specific natural killer (NK) cell engagers to treat certain types of cancer.\n<\/p>\n<p>\n<b>About Innate Pharma:<\/b>\n<\/p>\n<p>\nInnate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.\n<\/p>\n<p>\nInnate Pharma\u2019s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.\n<\/p>\n<p>\nInnate is a pioneer in the understanding of Natural Killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A\/S, Sanofi, and a multi-products collaboration with AstraZeneca.\n<\/p>\n<p>\nHeadquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.\n<\/p>\n<p>\nLearn more about Innate Pharma at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.innate-pharma.com&amp;esheet=52772896&amp;newsitemid=20220706005771&amp;lan=en-US&amp;anchor=www.innate-pharma.com&amp;index=3&amp;md5=68c03e651771c8029b904f41b37f168d\" rel=\"nofollow noopener\" shape=\"rect\">www.innate-pharma.com<\/a>\n<\/p>\n<p>\n<b>Information about Innate Pharma shares:<\/b>\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignl bwcellpmargin\">\n<b>ISIN code<\/b>\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nFR0010331421\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignl bwcellpmargin\">\n<b>Ticker code<\/b>\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nEuronext: IPH Nasdaq: IPHA\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignl bwcellpmargin\">\n<b>LEI<\/b>\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwvertalignt bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n9695002Y8420ZB8HJE29\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<div class=\"bwpagebreakafter\">\n<\/div>\n<p>\n<b>Disclaimer on forward-looking information and risk factors:<\/b>\n<\/p>\n<p>\nThis press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including \u201cbelieve,\u201d \u201cpotential,\u201d \u201cexpect\u201d and \u201cwill\u201d and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company\u2019s commercialization efforts, the Company\u2019s continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company\u2019s business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company&#8217;s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (\u201cFacteurs de Risque&#8221;) section of the Universal Registration Document filed with the French Financial Markets Authority (\u201cAMF\u201d), which is available on the AMF website <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.amf-france.org&amp;esheet=52772896&amp;newsitemid=20220706005771&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.amf-france.org&amp;index=4&amp;md5=a4ec85565eb7521b092db0a957c5d1ba\" rel=\"nofollow noopener\" shape=\"rect\">http:\/\/www.amf-france.org<\/a> or on Innate Pharma\u2019s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (\u201cSEC\u201d), including the Company\u2019s Annual Report on Form 20-F for the year ended December 31, 2021, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.\n<\/p>\n<p>\nThis press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>For additional information, please contact:<\/b>\n<\/p>\n<p>\n<b><span class=\"bwuline\">I<\/span><\/b><span class=\"bwuline\"><b>nvestors and Media<\/b><\/span>\n<\/p>\n<p>\n<b>I<\/b><b>nnate Pharma<\/b><br \/>Henry Wheeler<br \/>\n<br \/>Tel.: +33 (0)4 84 90 32 88<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;&#105;l&#x74;&#x6f;&#58;H&#x65;&#x6e;&#114;y&#x2e;&#x77;&#104;e&#x65;&#x6c;&#101;r&#x40;&#x69;&#110;n&#x61;&#x74;&#101;&#45;p&#x68;&#x61;&#114;m&#x61;&#x2e;&#102;r\" rel=\"nofollow noopener\" shape=\"rect\">&#72;&#x65;n&#114;&#x79;&#46;&#119;&#x68;e&#101;&#x6c;e&#114;&#x40;&#105;&#x6e;&#x6e;&#97;&#x74;&#x65;&#45;&#x70;h&#97;&#x72;m&#97;&#x2e;f&#114;<\/a>\n<\/p>\n<p>\n<b>ATCG Press<\/b><br \/>Marie Puvieux (France)<br \/>\n<br \/>Tel.: +33 981 87 46 72<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#116;&#111;&#58;in&#x6e;&#x61;&#x74;&#x65;&#x2d;&#112;&#104;&#97;rm&#x61;&#x40;&#x61;&#x74;&#x63;&#103;&#45;&#112;ar&#x74;&#x6e;&#x65;&#x72;&#x73;&#46;&#99;&#111;m\" rel=\"nofollow noopener\" shape=\"rect\">i&#110;&#110;&#x61;&#x74;e&#45;&#112;&#x68;&#x61;&#x72;m&#97;&#64;&#x61;&#x74;cg&#45;&#x70;&#x61;&#x72;t&#110;&#101;&#x72;&#x73;&#46;c&#111;&#x6d;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>IPH6401\/SAR\u2019514 is a BCMA-targeting NK cell engager using Sanofi\u2019s proprietary CROSSODILE\u00ae multi-functional platform. It was developed jointly and benefits from the dual NK targeting of Innate\u2019s ANKETTM proprietary platform Selection of IPH6401\/SAR\u2019514 triggers a \u20ac3M milestone payment to Innate MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/second-innate-pharma-nk-cell-engager-selected-by-sanofi-as-drug-candidate-for-development\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46415","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Second Innate Pharma NK Cell Engager Selected by Sanofi as Drug Candidate for Development - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/second-innate-pharma-nk-cell-engager-selected-by-sanofi-as-drug-candidate-for-development\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Second Innate Pharma NK Cell Engager Selected by Sanofi as Drug Candidate for Development - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"IPH6401\/SAR\u2019514 is a BCMA-targeting NK cell engager using Sanofi\u2019s proprietary CROSSODILE\u00ae multi-functional platform. It was developed jointly and benefits from the dual NK targeting of Innate\u2019s ANKETTM proprietary platform Selection of IPH6401\/SAR\u2019514 triggers a \u20ac3M milestone payment to Innate MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/second-innate-pharma-nk-cell-engager-selected-by-sanofi-as-drug-candidate-for-development\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-21T05:01:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220706005771\/en\/1245155\/21\/INNATEvertnoirDS.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/second-innate-pharma-nk-cell-engager-selected-by-sanofi-as-drug-candidate-for-development\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/second-innate-pharma-nk-cell-engager-selected-by-sanofi-as-drug-candidate-for-development\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Second Innate Pharma NK Cell Engager Selected by Sanofi as Drug Candidate for Development\",\"datePublished\":\"2022-07-21T05:01:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/second-innate-pharma-nk-cell-engager-selected-by-sanofi-as-drug-candidate-for-development\\\/\"},\"wordCount\":1025,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/second-innate-pharma-nk-cell-engager-selected-by-sanofi-as-drug-candidate-for-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220706005771\\\/en\\\/1245155\\\/21\\\/INNATEvertnoirDS.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/second-innate-pharma-nk-cell-engager-selected-by-sanofi-as-drug-candidate-for-development\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/second-innate-pharma-nk-cell-engager-selected-by-sanofi-as-drug-candidate-for-development\\\/\",\"name\":\"Second Innate Pharma NK Cell Engager Selected by Sanofi as Drug Candidate for Development - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/second-innate-pharma-nk-cell-engager-selected-by-sanofi-as-drug-candidate-for-development\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/second-innate-pharma-nk-cell-engager-selected-by-sanofi-as-drug-candidate-for-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220706005771\\\/en\\\/1245155\\\/21\\\/INNATEvertnoirDS.jpg\",\"datePublished\":\"2022-07-21T05:01:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/second-innate-pharma-nk-cell-engager-selected-by-sanofi-as-drug-candidate-for-development\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/second-innate-pharma-nk-cell-engager-selected-by-sanofi-as-drug-candidate-for-development\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/second-innate-pharma-nk-cell-engager-selected-by-sanofi-as-drug-candidate-for-development\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220706005771\\\/en\\\/1245155\\\/21\\\/INNATEvertnoirDS.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220706005771\\\/en\\\/1245155\\\/21\\\/INNATEvertnoirDS.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/second-innate-pharma-nk-cell-engager-selected-by-sanofi-as-drug-candidate-for-development\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Second Innate Pharma NK Cell Engager Selected by Sanofi as Drug Candidate for Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Second Innate Pharma NK Cell Engager Selected by Sanofi as Drug Candidate for Development - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/second-innate-pharma-nk-cell-engager-selected-by-sanofi-as-drug-candidate-for-development\/","og_locale":"en_US","og_type":"article","og_title":"Second Innate Pharma NK Cell Engager Selected by Sanofi as Drug Candidate for Development - Pharma Trend","og_description":"IPH6401\/SAR\u2019514 is a BCMA-targeting NK cell engager using Sanofi\u2019s proprietary CROSSODILE\u00ae multi-functional platform. It was developed jointly and benefits from the dual NK targeting of Innate\u2019s ANKETTM proprietary platform Selection of IPH6401\/SAR\u2019514 triggers a \u20ac3M milestone payment to Innate MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/second-innate-pharma-nk-cell-engager-selected-by-sanofi-as-drug-candidate-for-development\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-21T05:01:39+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220706005771\/en\/1245155\/21\/INNATEvertnoirDS.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/second-innate-pharma-nk-cell-engager-selected-by-sanofi-as-drug-candidate-for-development\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/second-innate-pharma-nk-cell-engager-selected-by-sanofi-as-drug-candidate-for-development\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Second Innate Pharma NK Cell Engager Selected by Sanofi as Drug Candidate for Development","datePublished":"2022-07-21T05:01:39+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/second-innate-pharma-nk-cell-engager-selected-by-sanofi-as-drug-candidate-for-development\/"},"wordCount":1025,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/second-innate-pharma-nk-cell-engager-selected-by-sanofi-as-drug-candidate-for-development\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220706005771\/en\/1245155\/21\/INNATEvertnoirDS.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/second-innate-pharma-nk-cell-engager-selected-by-sanofi-as-drug-candidate-for-development\/","url":"https:\/\/pharma-trend.com\/en\/second-innate-pharma-nk-cell-engager-selected-by-sanofi-as-drug-candidate-for-development\/","name":"Second Innate Pharma NK Cell Engager Selected by Sanofi as Drug Candidate for Development - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/second-innate-pharma-nk-cell-engager-selected-by-sanofi-as-drug-candidate-for-development\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/second-innate-pharma-nk-cell-engager-selected-by-sanofi-as-drug-candidate-for-development\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220706005771\/en\/1245155\/21\/INNATEvertnoirDS.jpg","datePublished":"2022-07-21T05:01:39+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/second-innate-pharma-nk-cell-engager-selected-by-sanofi-as-drug-candidate-for-development\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/second-innate-pharma-nk-cell-engager-selected-by-sanofi-as-drug-candidate-for-development\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/second-innate-pharma-nk-cell-engager-selected-by-sanofi-as-drug-candidate-for-development\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220706005771\/en\/1245155\/21\/INNATEvertnoirDS.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220706005771\/en\/1245155\/21\/INNATEvertnoirDS.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/second-innate-pharma-nk-cell-engager-selected-by-sanofi-as-drug-candidate-for-development\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Second Innate Pharma NK Cell Engager Selected by Sanofi as Drug Candidate for Development"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46415","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46415"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46415\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46415"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46415"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46415"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}